scholarly journals Differential Expression of Inflammation-Related Genes in Down Syndrome Patients with or without Periodontal Disease

2019 ◽  
Vol 2019 ◽  
pp. 1-6
Author(s):  
M. Baus-Domínguez ◽  
R. Gómez-Díaz ◽  
D. Torres-Lagares ◽  
J. R. Corcuera-Flores ◽  
J. C. Ruiz-Villandiego ◽  
...  

Aim. Aware that Down Syndrome patients present among their clinical characteristics impaired immunity, the aim of this study is to identify the statistically significant differences in inflammation-related gene expression by comparing Down Syndrome patients with Periodontal Disease (DS+PD+) with Down Syndrome patients without Periodontal Disease (DS+PD-), and their relationship with periodontitis as a chronic oral inflammatory clinical feature. Materials and Methods. Case study and controls on eleven Down Syndrome patients (DS+PD+ vs. DS+PD-). RNA was extracted from peripheral blood using a Qiagen PAXgene Blood miRNA Kit when performing an oral examination. A search for candidate genes (92 selected) was undertaken on the total genes obtained using a Scientific GeneChip® Scanner 3000 (Thermo Fisher Scientific) and Clariom S solutions for human, mouse, and rat chips, with more than 20,000 genes annotated for measuring expression levels. Results. Of the 92 inflammation-related genes taken initially, four genes showed a differential expression across both groups with a p value of <0.05 from the data obtained using RNA processing of the patient sample. Said genes were TNFSF13B (p=0.0448), ITGB2 (p=0.0033), ANXA3 (p=0.0479), and ANXA5 (p=0.016). Conclusions. There are differences in inflammation-related gene expression in Down Syndrome patients when comparing patients who present a state of chronic oral inflammation with patients with negative rates of periodontal disease.


2020 ◽  
Vol 9 (8) ◽  
pp. 2525
Author(s):  
Maria Baus-Domínguez ◽  
Raquel Gómez-Díaz ◽  
Jose-Ramón Corcuera-Flores ◽  
Daniel Torres-Lagares ◽  
José-Cruz Ruiz-Villandiego ◽  
...  

Peri-implant bone loss leading to dental implant failure does not develop in the same way across subjects who apparently present the same condition—specifically, in the case of Down syndrome patients with the same genetic disorder—given that they do not necessarily develop immune–inflammatory disorders to the same extent. Methods: This retrospective case-control study was aimed at identifying the possible genes involved in implant failure in Down syndrome patients by matching the periodontal disease variable by means of a retrospective case-control study. This process involved using the functional analysis of gene expression software Transcriptome Analysis Console (TAC, Affymetrix, Thermo Fisher Scientific, Waltham, MA, USA) and a search for the possible candidate genes involved. Focus was placed on the 92 genes related to the inflammation identified from the TaqMan™ Array Plate Human Inflammation Kit (Thermo Fisher Scientific, Waltham, MA, USA). Results: Six genes showed statistically significant results (p < 0.05) in our comparison. Three of them—PLCG2 (p = 0.0333), ALOX5 (p = 0.03) and LTAH4 (p = 0.0081)—were overexpressed in the implant reject group, and the following three were down-regulated: VCAM1 (p = 0.0182), PLA2G2A (p = 0.0034) and PLA2G10 (p = 0.047). Conclusion: Statistically significant differences exist in the gene expression involved in osteoclastogenesis, inflammatory response and host defensive response.



Author(s):  
Л.М. Кожевникова ◽  
И.Б. Цорин ◽  
В.Н. Столярук ◽  
М.Б. Вититнова ◽  
В.В. Барчуков ◽  
...  

Цель исследования - оценка уровня экспрессии генов рецепторных и регуляторных белков, участвующих в процессах ремоделирования и сократимости миокарда у крыс с хронической сердечной недостаточностью. Методика. Использован комплекс эхокардиографических и молекулярно-биологических методов исследования. Экспрессию генов оценивали по уровню мРНК в образцах тканей левого желудочка крыс на 92 сут. после перевязки коронарной артерии (опытная группа) или подведения лигатуры под коронарную артерию (группа сравнения). Выделение РНК из тканей левого желудочка сердца проводили с помощью набора GeneJET, синтез кДНК - используя набор RevertAid H Minus First Strand cDNA Synthesis Kit («Thermo Fisher Scientific», США), ПЦР-РВ проводили с помощью набора qPCRmix-HS («Евроген», Россия), используя праймеры и флуоресцентные зонды («ДНК-синтез», Россия), согласно протоколам производителей. Результаты. Установлено, что хроническая сердечная недостаточность (ХСН) формируется через 90 сут. после воспроизведения переднего трансмурального инфаркта миокарда, о чем свидетельствовало снижение инотропной функции сердца и увеличение конечно-систолического и конечно-диастолического размеров левого желудочка сердца. Показано, что при ХСН повышается экспрессия генов, причастных к ремоделированию миокарда. Так, в биоптатах левого желудочка сердца крыс с ХСН на 41% (p = 0,006) возрастает уровень мРНК для ангиотензиновых рецепторов AT1А-типа, на 33% (р = 0,01) для вазопрессиновых V1A-R и на 71% (p = 0,01) для эндотелиновых ETA-R по сравнению с аналогичными показателями у ложнооперированных животных. У крыс с ХСН уровень мРНК b-AR и b-AR в левом желудочке превышал таковой у ложнооперированных животных соответственно на 35% (p = 0,001) и 48% (p = 0,0001). Выявлен высокий уровень экспрессии генов белков Epac2 и СаМ, играющих ключевую роль в аритмогенезе, что свидетельствует о высокой степени риска развития аритмий при ХСН. Установлено, что у животных с ХСН уровень мРНК для Sigma-R в биоптатах тканей миокарда левого желудочка возрастает на 74% (p = 0,0001) по сравнению с уровнем мРНК в сердцах ложнооперированных крыс, что, по-видимому, носит компенсаторный характер, направленный на поддержание протеостаза, модуляцию активности различных ионных каналов и нормализацию биоэнергетических процессов в миокарде. Заключение. Таким образом, при ХСН в левом желудочке сердца крыс повышается экспрессия генов рецепторных и регуляторных белков, участвующих в процессах ремоделирования миокарда, что может быть одним из механизмов нарушения сократимости миокарда и возникновения злокачественных нарушений сердечного ритма, которые отягощают течение данного заболевания. The purpose. The purpose of the study is to assess the level of expression of receptor and regulatory proteins genes involved in remodeling and myocardial contractility in rats with chronic heart failure. Methods. A complex of echocardiographic and molecular biological research methods was used. Gene expression was assessed by the level of mRNA in tissue samples of the left ventricle of rats extracted on day 92 after the coronary artery ligation (CHF group) or summation of the ligature under the coronary artery (sham-operated group). RNA isolation from the left ventricular tissue of the heart was performed using the GeneJET kit, cDNA synthesis using the RevertAidTM H Minus First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, USA), PCR-RV was performed using the qPCRmix-HS kit (Evrogen, Russia), using primers and fluorescent probes (DNA synthesis, Russia), according to manufacturers protocols. Results. It has been established that chronic heart failure (CHF) is formed 90 days after the reproduction of anterior transmural myocardial infarction, as evidenced by a decrease in heart pumping function and an increase in the end-systolic and end-diastolic sizes of the heart left ventricle. It is shown that CHF increases the expression of genes involved in myocardial remodeling. Thus, in left ventricular biopsy samples of rats with CHF, the level of mRNA for angiotensin receptors of AT1A type increases by 41% (p = 0.006), by 33% (p = 0.01) for vasopressin V1A-R and by 71% (p = 0.01) for endothelin ETA-R compared with similar indicators in sham-operated animals. In rats with CHF, the b1-AR and b2-AR mRNA levels in the left ventricle exceeded that in the sham-operated animals, respectively, by 35% (p = 0.001) and 48% (p = 0.0001). A high level of gene expression of the Epac2 and CaM proteins, which play a key role in arrhythmogenesis, is evidenced, which indicates a high risk of developing arrhythmias in CHF. In animals with CHF, the level of mRNA for Sigma-R in biopsy specimens of left ventricular myocardial tissue was found to increase by 74% (p = 0.0001) compared to the level of mRNA in the hearts of sham-operated rats, that apparently has compensatory character at maintaining proteostasis, modulating the activity of various ion channels and normalizing bioenergetic processes in the myocardium. Conclusion. Thus, with CHF in the left ventricle of the rat heart, gene expression of receptor and regulatory proteins involved in myocardial remodeling increases, which can be one of the mechanisms of violation of myocardial contractility and the occurrence of malignant heart rhythm disorders that make it difficult for the disease.



2013 ◽  
Vol 04 (12) ◽  
pp. 64-73 ◽  
Author(s):  
Alice Casassola ◽  
Sandra Patussi Brammer ◽  
Márcia Soares Chaves ◽  
José Antônio Martinelli ◽  
Magali Ferrari Grando ◽  
...  


2018 ◽  
Vol 6 (1) ◽  
pp. 33-39
Author(s):  
Neha Mago ◽  
Nishad Deshpande

Innovation and technology are considered as a subject of success and achievement to the firm. The comparative study represents an essential procedure to identify the innovation and technological capabilities of major players involved in the bioinformatics related inventions. The aim of the research is to map out the top firms and identify their strategically important technologies. In view of this, the comparative analysis of major firms in bioinformatics industry is carried out using patent information. Herein the top three assignees are considered and based on this further analysis is performed. The top companies’ trend suggests that Thermo Fisher Scientific Inc. is the major player in bioinformatics research. Thus, we have tried to develop an overview on their patenting trend and important concerned areas of research. Also, our results indicate that the application of computational tools is being utilized for most of the research areas like the study of genomics and proteomics, sequence categorization and their structural prediction.



Genes ◽  
2019 ◽  
Vol 10 (9) ◽  
pp. 711
Author(s):  
Maria Baus-Domínguez ◽  
Raquel Gómez-Díaz ◽  
Jose-Ramón Corcuera-Flores ◽  
Daniel Torres-Lagares ◽  
José-Cruz Ruiz-Villandiego ◽  
...  

Background: Sometimes dental implants seem to be the only therapeutic alternative for the oral rehabilitation of patients with Down syndrome, given that they usually lose all their teeth early due to suffering aggressive periodontitis and they do not usually have the skills required to wear removable prostheses. However, the evolution of dental implants in these patients shows very adverse results. It is possible that basal genetic alterations, or at least some characteristics of these, may underlie these clinical results. The metabolic pathway of metallothioneins, molecules with an important influence on bone metabolism, could be one of the said alterations. Aims: To determine whether the expression of metallothioneins (MTs) and their metabolic pathway may be identified and related to the periodontitis and lack of osseointegration of dental implants in Down syndrome patients. Materials and Methods: Retrospective study of cases and controls by comparing patients with Down syndrome, periodontal disease, and implant failure (four patients, test group) with patients with Down syndrome, without periodontal disease, and without implant failure after two years of following (seven patients, control group), by extracting peripheral blood at the time of the dental examination to extract RNA and its subsequent processing in relation to gene expression of the metabolic pathway of metallothioneins. Results: The results identified low expression in the group of patients with periodontal disease and implant failure of genes MT1E, MT1H, MT1X, MT1A, MT1B, MT1C, MT1L, MT2A, MT1M, and MT1G. Conclusions: The low MT1 and MT2 gene expression seems to be related to the onset of periodontal disease and implant rejection in Down syndrome patients, although more data are required to confirm whether this relationship is due to one of the two conditions, to both independently, or to the two jointly—this last option being indicated by our current study.



Gene Therapy ◽  
2021 ◽  
Author(s):  
Anqi Li ◽  
David James ◽  
Rebecca Lim

AbstractThe Gibco™ CTS™ Rotea™ Counterflow Centrifugation System is an automated cell processing device developed for manufacturing cell therapy products. The developer (Scinogy Pty Ltd) collaborated with Thermo Fisher Scientific to successfully launch the product in late 2020, completing product development from concept to international sales in <3years. This article describes the origin story of the Rotea system and how a chance meeting between a co-inventor of the Rotea system and an academic cell biologist took the invention from a garage workshop to the world stage. We describe the contribution of academic research to the innovation value chain and importance of academic institutions being industry-ready to support such collaborations.



F1000Research ◽  
2019 ◽  
Vol 8 ◽  
pp. 886 ◽  
Author(s):  
Malte Thodberg ◽  
Albin Sandelin

Cap Analysis of Gene Expression (CAGE) is one of the most popular 5'-end sequencing methods. In a single experiment, CAGE can be used to locate and quantify the expression of both Transcription Start Sites (TSSs) and enhancers. This is workflow is a case study on how to use the CAGEfightR package to orchestrate analysis of CAGE data within the Bioconductor project. This workflow starts from BigWig-files and covers both basic CAGE analyses such as identifying, quantifying and annotating TSSs and enhancers, advanced analysis such as finding interacting TSS-enhancer pairs and enhancer clusters, to differential expression analysis and alternative TSS usage. R-code, discussion and references are intertwined to help provide guidelines for future CAGE studies of the same kind.



Sign in / Sign up

Export Citation Format

Share Document